Sanofi CEO Takes Not-So-Slow And Steady Approach To COVID-19 Vaccines
'It's not a race between companies, it's a race against an enemy'
Pfizer and BioNTech may be first out of the gate with robust results for a COVID-19 vaccine but amid all the excitement, Paul Hudson has issued a timely reminder that multiple vaccines will be needed to meet the huge demand.
You may also be interested in...
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
Join us for a brief audio tour around key developments in the global biopharma industry over the past week, in this podcast version of Scrip's Five Must-Know Things.
The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.